Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$14.00 -3.6%	$14.24	$10.57 ▼ $33.33	$2.03B	1.33	1.15 million shs	1.31 million shs
MIRM Mirum Pharmaceuticals	$51.93 -1.5%	$48.30	$36.20 ▼ $54.78	$2.57B	0.97	449,209 shs	255,993 shs
QURE uniQure	$14.99 -1.4%	$14.76	$4.45 ▼ $19.18	$821.09M	0.08	1.43 million shs	1.79 million shs
SDGR Schrodinger	$21.45 -0.9%	$21.94	$16.60 ▼ $28.47	$1.57B	1.58	928,386 shs	962,275 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	-3.65%	-3.58%	-0.64%	+9.89%	-39.16%
MIRM Mirum Pharmaceuticals	-1.52%	-1.39%	+2.22%	+32.81%	+35.34%
QURE uniQure	-1.38%	+4.10%	-0.73%	+15.31%	+76.98%
SDGR Schrodinger	-0.92%	+2.09%	+1.90%	-16.70%	-7.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNLI Denali Therapeutics	4.5825 of 5 stars	4.5	1.0	4.7	3.2	3.3	0.0
MIRM Mirum Pharmaceuticals	3.7789 of 5 stars	3.6	0.0	4.2	2.6	1.7	0.6
QURE uniQure	1.79 of 5 stars	3.5	1.0	0.0	0.6	2.5	0.6
SDGR Schrodinger	2.0271 of 5 stars	3.4	1.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNLI Denali Therapeutics	3.06	Buy	$33.71	140.82% Upside
MIRM Mirum Pharmaceuticals	3.13	Buy	$65.50	26.13% Upside
QURE uniQure	2.91	Moderate Buy	$37.82	152.29% Upside
SDGR Schrodinger	2.75	Moderate Buy	$32.75	52.68% Upside

Current Analyst Ratings Breakdown

Latest QURE, MIRM, SDGR, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00
7/11/2025	MIRM Mirum Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00
5/30/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00
5/29/2025	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/19/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$73.00
5/19/2025	QURE uniQure	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$73.00 ➝ $77.00
5/12/2025	QURE uniQure	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNLI Denali Therapeutics	$330.53M	6.15	N/A	N/A	$8.53 per share	1.64
MIRM Mirum Pharmaceuticals	$379.25M	6.78	N/A	N/A	$4.70 per share	11.05
QURE uniQure	$27.12M	30.28	N/A	N/A	($0.14) per share	-107.07
SDGR Schrodinger	$207.54M	7.58	N/A	N/A	$5.78 per share	3.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.61	N/A	N/A	N/A	-20.39%	-33.63%	-11.50%	8/6/2025 (Estimated)
QURE uniQure	-$239.56M	-$4.39	N/A	N/A	N/A	-1,077.05%	-483.87%	-34.28%	8/7/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	N/A	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)

Latest QURE, MIRM, SDGR, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	DNLI Denali Therapeutics	-$0.73	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	QURE uniQure	-$0.89	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	MIRM Mirum Pharmaceuticals	-$0.31	N/A	N/A	N/A	$107.91 million	N/A
7/30/2025	Q2 2025	SDGR Schrodinger	-$0.83	N/A	N/A	N/A	$52.03 million	N/A
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
5/9/2025	Q1 2025	QURE uniQure	-$1.07	-$0.82	+$0.25	-$0.82	$5.93 million	$1.57 million
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNLI Denali Therapeutics	N/A	9.56	9.56
MIRM Mirum Pharmaceuticals	1.32	3.22	3.04
QURE uniQure	1.53	11.99	11.99
SDGR Schrodinger	N/A	3.45	3.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNLI Denali Therapeutics	92.92%
MIRM Mirum Pharmaceuticals	N/A
QURE uniQure	78.83%
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
DNLI Denali Therapeutics	12.50%
MIRM Mirum Pharmaceuticals	14.36%
QURE uniQure	4.79%
SDGR Schrodinger	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.54 million	42.42 million	Optionable
QURE uniQure	500	54.78 million	52.15 million	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable

QURE, MIRM, SDGR, and DNLI Headlines

Recent News About These Companies

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

July 18 at 10:25 AM | globenewswire.com

Massachusetts Financial Services Co. MA Sells 186,228 Shares of Schrodinger, Inc. (NASDAQ:SDGR)

July 18 at 5:38 AM | marketbeat.com

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

July 17 at 10:30 AM | finance.yahoo.com

Schrodinger (NASDAQ:SDGR) Given New $30.00 Price Target at KeyCorp

July 15, 2025 | americanbankingnews.com

KeyCorp Has Lowered Expectations for Schrodinger (NASDAQ:SDGR) Stock Price

July 14, 2025 | marketbeat.com

Schrodinger, Inc. (NASDAQ:SDGR) Position Raised by Stephens Investment Management Group LLC

July 13, 2025 | marketbeat.com

BMO Capital Remains a Buy on Schrodinger (SDGR)

July 11, 2025 | theglobeandmail.com

Morgan Stanley Assumes Coverage on Schrödinger (SDGR) Stock

July 10, 2025 | finance.yahoo.com

Allspring Global Investments Holdings LLC Boosts Holdings in Schrodinger, Inc. (NASDAQ:SDGR)

July 7, 2025 | marketbeat.com

SDGR - Schrodinger Inc Ordinary Shares Financials - Morningstar

July 5, 2025 | morningstar.comM

MS initiates coverage on AI Biotechs, flags key pipeline catalysts

July 3, 2025 | investing.com

Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505

July 3, 2025 | msn.com

Morgan Stanley Initiates Coverage on Schrodinger (NASDAQ:SDGR)

July 3, 2025 | marketbeat.com

Schrödinger, Inc. (SDGR) - Yahoo Finance

July 2, 2025 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

July 2, 2025 | prnewswire.com

Short SDGR: Schrödinger bounces from 2024 midpoint, trading range low as potential short-term target

July 1, 2025 | invezz.comI

Sumitomo Mitsui Trust Group Inc. Sells 48,103 Shares of Schrodinger, Inc. (NASDAQ:SDGR)

July 1, 2025 | marketbeat.com

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

June 27, 2025 | tmcnet.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 23, 2025 | globenewswire.com

17,493 Shares in Schrodinger, Inc. (NASDAQ:SDGR) Bought by Palumbo Wealth Management LLC

June 23, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 22, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, MIRM, SDGR, and DNLI Company Descriptions

Denali Therapeutics NASDAQ:DNLI

$14.00 -0.53 (-3.65%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$14.00 -0.01 (-0.04%)

As of 07/18/2025 07:57 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$51.93 -0.80 (-1.52%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$51.92 -0.02 (-0.03%)

As of 07/18/2025 07:46 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

uniQure NASDAQ:QURE

$14.99 -0.21 (-1.38%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$14.94 -0.04 (-0.30%)

As of 07/18/2025 07:28 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Schrodinger NASDAQ:SDGR

$21.45 -0.20 (-0.92%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$21.74 +0.29 (+1.33%)

As of 07/18/2025 07:57 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time